Finding. Karadimov, Kim, Fu and colleagues show that the mitochondrial ClpP agonist TR-107 kills adrenocortical carcinoma at nanomolar concentrations in two cell lines and in patient-derived organoids. Oxygen consumption falls. ROS rise. Ferroptosis-rheostat proteins come up. The compound is not an ABCB1 substrate, and it synergizes with IGF-1R inhibitors.
Why this paper matters
ACC is rare, steroid-producing, and metabolically loud. The adrenal cortex already runs a mitochondrial factory for hormone synthesis; the carcinoma keeps that factory and adds IGF-2 drive. Cytotoxic options are thin. That makes a mitochondrial protease an unusually on-target idea rather than a generic “hit the powerhouse” slogan.
ClpP agonism is an established preclinical strategy: hyperactivate the matrix protease, degrade the mitochondrial proteome, and watch OXPHOS fail. TR-107 is presented as a selective small-molecule agonist in that class. The ACC-specific contribution is the disease context — steroidogenic mitochondria, IGF-2/IGF-1R signaling, and a check against the most common efflux pump — plus organoids, not only NCI-H295R.
What they actually measured
TR-107 cut viability and confluency in NCI-H295R, mACC3, and short-term ACC PDOs at nanomolar doses. Metabolic analysis showed impaired oxygen consumption, disrupted oxidative phosphorylation, and attenuated basal respiration. ROS increased with dose. Proteins that set the ferroptotic rheostat were upregulated. Pharmacokinetic/transport work found TR-107 is not an ABCB1/MDR1/P-glycoprotein substrate. Because IGF-2 signaling is central to ACC, they combined TR-107 with IGF-1R inhibitors and report synergistic viability loss across the same three model classes.
That is a clean preclinical package: target, bioenergetic endpoint, death-mode hint, resistance-relevant property, rational combination.
How to read the score
Mitochondrial relevance is direct — ClpP, OCR, ROS. Translational signal is strong for a preclinical paper. Confidence is high that TR-107 damages ACC mitochondria in these models. Confidence is lower that ferroptosis is the killing mechanism (the abstract shows rheostat proteins and ROS, not a full rescue) and lower still that patients will benefit. Organoids are not a registration study. ClpP agonists as a class have a history of looking potent in dishes.
Score 87 is “serious ACC mitochondrial pharmacology,” not “new standard of care.”
What to do with it
If you follow imipridones or ClpP activators, add ACC to the indication list and keep OCR plus ClpP occupancy as primary endpoints. If you follow ACC, treat IGF-1R blockade as a combination hypothesis with a mitochondrial partner rather than as monotherapy déjà vu. If you follow multidrug resistance, the ABCB1-negative result is worth replicating in other pumps. Do not write a clinical-use sentence from this brief. The next paper that matters is in vivo ACC — xenograft or PDOX — with steroid output and normal adrenal toxicity measured on the same animals.